We are seeing patients in-person and through Video Visits. Learn more about how we’re keeping you safe and please review our updated visitor policy. Please also consider supporting Weill Cornell Medicine’s efforts to support our front-line workers.

Convection-Enhanced Delivery of 124I-8H9 for Patients With Non-Progressive Diffuse Pontine Gliomas Previously Treated With External Beam Radiation Therapy

You are here

Dr. Mark SouweidaneDiffuse Intrinsic Pontine Glioma (DIPG) is a rare, inoperable, and uniformly fatal brain tumor that strikes young children. Surgical removal is not possible due to the location and diffuse nature of the tumor. Chemotherapy has proven ineffective due to the protective nature of the blood-brain barrier. Radiation is the standard treatment for DIPG, but it does not provide a cure; most patients die within months of diagnosis. This study tests an innovative convection-enhanced delivery (CED) technique that places a radioactive therapeutic agent (124I-8H9) at the site of the tumor using a surgically placed cannula. This trial is the first time CED has been used to administer 124I-8H9, shown to be safe in animals, to a human brain. It is open to patients between the ages of 3 and 21 who have undergone external beam radiotherapy at least 4 weeks but no more than 14 weeks before enrollment. The study is being conducted in partnership with Memorial Sloan-Kettering Cancer Center.

PI: Mark Souweidane, M.D.


The initial Phase I trial is now complete.
Patients continue to be enrolled for treatment
as Dr. Souweidane and his team
are working on next steps.


Email: mmsouwei@med.cornell.edu

Get more information about the trial
Read the trial listing on clinicaltrials.gov
Find out more about DIPG